MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% – Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s stock price traded down 5.3% during mid-day trading on Tuesday . The company traded as low as $16.55 and last traded at $16.4080. 560,651 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 1,463,796 shares. The stock had previously closed at $17.33.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong Phase 3 psoriatic arthritis results: MoonLake reported that sonelokimab met all primary and secondary clinical goals in the Phase 3 IZAR-1 trial at Week 16. In the 60 mg induction group, 42.1% of patients achieved ACR50, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90 and 41.2% achieved minimal disease activity. The results support the drug’s potential in psoriatic arthritis and could strengthen its regulatory and commercial outlook. Reuters article
• Positive Sentiment: Improved financial result and ample liquidity: Second-quarter adjusted results included a loss of $0.84 per share, narrower than the $0.92 analyst consensus. MoonLake ended the quarter with $537 million in cash, cash equivalents and short-term marketable securities, expects its cash runway to extend through mid-2028, and said up to $400 million remains available under its Hercules Capital facility. MoonLake Q2 results article
• Positive Sentiment: Upcoming catalysts: MoonLake expects to complete IZAR-2 enrollment in the third quarter of 2026 and submit a biologics license application for sonelokimab in hidradenitis suppurativa by the end of September.
• Neutral Sentiment: Options activity increased: Traders purchased 2,707 call options, about 142% above typical daily volume, indicating heightened interest and potentially bullish speculation, though options activity does not confirm sustained buying in the shares.
• Neutral Sentiment: Analyst stance remains cautious: Brokerages give MLTX an average “Hold” recommendation, suggesting the positive trial data may already be partly reflected in valuation.
• Negative Sentiment: Ongoing losses and insider selling: MoonLake reported a $61.8 million quarterly net loss, including $50.2 million in research and development expenses. Separately, company insiders reportedly made no open-market purchases and sold shares in the past six months, which may weigh on investor sentiment.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Friday. Needham & Company LLC upped their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, July 20th. Finally, Leerink Partners boosted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $24.21.

MoonLake Immunotherapeutics Price Performance

The company has a market capitalization of $1.19 billion, a PE ratio of -4.20 and a beta of 1.06. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. The company’s 50 day moving average price is $19.02 and its 200-day moving average price is $17.89.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Monday, August 10th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.08. On average, sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider directly owned 2,824,551 shares of the company’s stock, valued at $54,881,025.93. The trade was a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the sale, the chief executive officer directly owned 2,774,893 shares of the company’s stock, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 344,800 shares of company stock worth $6,820,071. Company insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $26,000. Bank of America Corp DE boosted its position in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics in the fourth quarter valued at about $47,000. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.